Histamine H3 receptor antagonists: From target identification to drug leads

Biochemical Pharmacology

Volumn 73, Issue 8, 2007, Pages 1084-1096

  Bonaventure, P ^a   Letavic, M ^a   Dugovic, C ^a   Wilson, S ^a   Aluisio, L ^a   Pudiak, C ^a   Lord, B ^a   Mazur, C ^a   Kamme, F ^a   Nishino, S ^b   Carruthers, N ^a   Lovenberg, T ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Cognition; Histamine H3 receptor; JNJ 10181457; JNJ 5207852; Narcolepsy

Indexed keywords

ACETYLCHOLINE; AMPHETAMINE; CLOBENPROPIT; DESIPRAMINE; DOPAMINE; GT 2331; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOPYRIDINE DERIVATIVE; JNJ 10181457; JNJ 10266386; JNJ 132600; JNJ 280566; JNJ 5207852; JNJ 6379490; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; PSYCHOSTIMULANT AGENT; RWJ 662733; THIOPERAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; 4 (3 (4 PIPERIDIN 1 YLBUT 1 YNYL)BENZYL)MORPHOLINE; 4-(3-(4-PIPERIDIN-1-YLBUT-1-YNYL)BENZYL)MORPHOLINE; ANTIHISTAMINIC AGENT; COMPLEMENTARY DNA; DIAMINE; JNJ-5207852; MORPHOLINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ARTICLE; BRAIN REGION; CATALEPSY; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; FRONTAL CORTEX; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; LOCOMOTION; MEMORY DISORDER; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; GENETICS; ISOLATION AND PURIFICATION; MALE; METABOLISM; MOLECULAR CLONING; NARCOLEPSY; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; CLONING, MOLECULAR; COGNITION DISORDERS; DIAMINES; DNA, COMPLEMENTARY; HISTAMINE ANTAGONISTS; HUMANS; MALE; MORPHOLINES; NARCOLEPSY; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H3;

EID: 33947119591     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.031     Document Type: Article

References (66)

1. Barger G., and Dale H.H. Chemical structure and sympathomimetic action of amines. J Physiol (London) 41 (1911) 19-59
2. Ash A.S.F., and Schild J.O. Receptors mediating some action of histamine. Br J Pharmacol Chemother 27 (1966) 427-439
3. 2-receptors. Nature 236 (1972) 385-390
4. 2 receptors in the histamine-induced accumulation of cyclic AMP in guinea pig brain slices. Nature 253 (1975) 362-364
5. Schwartz J.C., Lampart C., Rose C., Rehault M.C., Bischoff S., and Pollard H. Development of histaminergic systems in the newborn rat brain. J Physiol (Paris) 62 Suppl 3 (1970) 447
6. Brown R.E., Stevens D.R., and Haas H.L. The physiology of brain histamine. Prog Neurobiol 63 (2001) 637-672
7. 3) of histamine receptor. Nature 302 (1983) 832-837
8. 3-receptors. Nature 327 (1987) 117-123
9. Hill S.J., Ganellin C.R., Timmerman H., Schwartz J.C., Shankley N.P., Young J.M., et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49 (1997) 253-278
10. 3-receptor. A target for developing new drugs. Prog Drug Res 39 (1992) 127-165
11. 3 antagonists/inverse agonists. Biochem Pharmacol 71 (2006) 1103-1113
12. 3 receptor. Prog Med Chem 44 (2006) 181-206
13. 3 receptor antagonists reach out for the clinic. Drug Discov Today 10 (2005) 1613-1627
14. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25 (2004) 618-625
15. 3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 103 (2004) 1-20
16. 3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 14 (2005) 223-241
17. 3 receptor. Mol Pharmacol 55 (1999) 1101-1107
18. 3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther 293 (2000) 771-778
19. 3 receptor drugs. Nat Rev Drug Discov 4 (2005) 107-120
20. 3 receptor. Eur J Pharmacol 467 (2003) 57-65
21. 3 receptor. Neuroreport 11 (2000) L3-L4
22. 3 receptor antagonists. J Med Chem 42 (1999) 903-909
23. 3 receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol 131 (2000) 1247-1250
24. 3-receptor isoforms. Inflamm Res 53 (2004) 509-516
25. 3 receptor. Neuropharmacology 42 (2002) 929-940
26. 3 receptor gene (HRH3) and identification of naturally occurring variations. J Neural Transm 109 (2002) 443-453
27. 3 receptor mRNA at the third cytoplasmic loop is not detectable in humans. Mol Brain Res 83 (2000) 145-150
28. 3 antagonists. J Pharmacol Exp Ther 299 (2001) 908-914
29. 3 receptors. Br J Pharmacol 135 (2002) 383-392
30. 3 receptors regulates histamine neurons in brain. Nature 408 (2000) 860-864
31. 3 receptors in vitro and in vivo. Ann NY Acad Sci 100 (2003) 11086-11091
32. Sanfilippo P.J., Urbanski M., Press J.B., Dubinsky B., and Moore Jr. J.B. Synthesis of (aryloxy)alkylamines. 2. Novel imidazo-fused heterocycles with calcium channel blocking and local anesthetic activity. J Med Chem 31 (1988) 2221-2227
33. 3 receptor antagonists: 4-(aminoalkoxy)benzylamines. J Med Chem 46 (2003) 3938-3944
34. 3 antagonist. Br J Pharmacol 143 (2004) 649-661
35. 3-receptor antagonist. J Pharmacol Exp Ther 287 (1998) 658-666
36. Parmentier R., Ohtsu H., Djebbara-Hannas Z., Valatx J.-L., Watanabe T., and Lin J.-S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 22 (2002) 7695-7711
37. Masaki T., Yoshimatsu H., Chiba S., Watanabe T., and Sakata T. Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 50 (2001) 376-384
38. 3 receptors and the pharmacology of its ligands. Nippon Shinkei Seishin Yakurigaku Zasshi 15 (1995) 87-102
39. 3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci 69 (2001) 469-478
40. 3 receptor antagonist, powerfully suppresses peptide YY-induced food intake in rats. Biol Psychiatr 45 (1999) 475-481
41. 3 receptors results in changes in brain histamine tone leading to an obese phenotype. J Clin Invest 110 (2002) 1791-1799
42. 3 receptors. Mol Pharmacol 62 (2002) 389-397
43. Laposky A., Shelton J., Turek F., Bass J., and Lovenberg T. The effect of leptin on sleep is absent in histamine-3 receptor deficient mice. Sleep 29 (2006) A29
44. Yoshimatsu H., Itateyama E., Kondou S., Tajima D., Himeno K., Hidaka S., et al. Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes 48 (1999) 2286-2291
45. 3 antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology 50 (2006) 404-411
46. 3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 29 (2006) A230
47. Carruthers N. Histamine H3 antagonists: potential applications for the treatment of excessive sleepiness and attention disorders. ASPET Annual Meeting, Symposium in Memoriam, Arthur Hancock, Ph.D. (1949-2005). San Francisco, 2006.
48. 3 receptor antagonist, GT-2332, on rat sleep/wakefulness and canine cataplexy. Soc Neurosci 25 (1999) 1134
49. Nishino S., Okura M., and Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 4 (2000) 57-99
50. 3 receptor in the rat hippocampus. Brain Res 788 (1998) 179-186
51. 3 receptor (H3R) antagonist with cognition enhancing properties in rats. Inflamm Res 52 (2003) S31-S32
52. Lin J.-S., Sakai K., Vanni-Mercier G., Arrang J.-M., Garbarg M., Schwartz J.-C., et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 523 (1990) 325-330
53. 3-receptor ligands: an electrophysiological study in freely moving cats. Behav Brain Res 144 (2003) 227-241
54. Scammell T.E., Estabrooke I.V., McCarthy M.T., Chemelli R.M., Yanagisawa M., Miller M.S., et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 20 (2000) 8620-8628
55. Lin J.-S., Hou Y., and Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 93 (1996) 14128-14133
56. Edgar D.M., and Seidel W.F. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 283 (1997) 757-769
57. Estabrooke I.V., McCarthy M.T., Ko E., Chou T.C., Chemelli R.M., Yanagisawa M., et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci 21 (2001) 1656-1662
58. 1 receptor knockout mice. Proc Natl Acad Sci USA 103 (2006) 4687-4692
59. 3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology 167 (2003) 363-372
60. Mignot E., and Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep 28 (2005) 754-763
61. 3 receptor antagonist. J Pharmacol Exp Ther 313 (2005) 176-190
62. 3 receptor activation in rats. Br J Pharmacol 119 (1996) 1656-1664
63. Fox G.B., Pan J.B., Esbenshade T.A., Bennani Y.L., Black L.A., Faghih R., et al. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131 (2002) 151-161
64. Sagvolden T., Russell V.A., Aase H., Johansen E.B., and Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatr 57 (2005) 1239-1247
65. Huss M., and Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal, and clinical studies. J Atten Disord 6 Suppl. 1 (2002) S65-S71
66. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, San Diego